Drug Search Results
More Filters [+]

Elacytarabine

Alternative Names: elacytarabine, cp-4055, cp4055, cp 4055
Latest Update: 2013-09-27
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Global Transcription Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Clavis Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Elacytarabine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Acute Myeloid Leukemia|Leukemia

Phase 2: Acute Myeloid Leukemia|Chronic Lymphoid Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Melanoma|Leukemia|Ovarian Cancer|Colorectal Cancer

Phase 1: Healthy Volunteers|Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2008-008518-38

P2

Terminated

Leukemia

2013-05-07

CP-4055

P1

Completed

Leukemia

2013-05-01

CP4055-205

P2

Completed

Acute Myeloid Leukemia

2013-05-01

CP4055-110

P1

Completed

Healthy Volunteers

2013-02-01

Recent News Events

Date

Type

Title